UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e002068

2021

Volltextzugriff (PDF)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Cancer medicine (Malden, MA), 2021-05, Vol.10 (9), p.3059-3067

2021

Volltextzugriff (PDF)

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Volltextzugriff (PDF)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

British journal of cancer, 2018-11, Vol.119 (10), p.1208-1214

2018

Volltextzugriff (PDF)

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1108-1118

2021

Volltextzugriff (PDF)

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Clinical cancer research, 2015-02, Vol.21 (3), p.553-560

2015

Volltextzugriff (PDF)

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-08, Vol.18 (8), p.1146-1156

2016

Volltextzugriff (PDF)

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2015-12, Vol.76 (6), p.1143-1152

2015

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357-370

2015

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Cancer chemotherapy and pharmacology, 2019-11, Vol.84 (5), p.1003-1015

2019

Volltextzugriff (PDF)

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

British journal of clinical pharmacology, 2014-05, Vol.77 (5), p.796-807

2014

Volltextzugriff (PDF)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309-323

2015

Volltextzugriff (PDF)

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

The AAPS journal, 2015-11, Vol.17 (6), p.1395-1406

2015

Volltextzugriff (PDF)

Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage

British journal of clinical pharmacology, 2008-03, Vol.65 (3), p.317-325

2008

Volltextzugriff (PDF)

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials

British journal of clinical pharmacology, 2010-10, Vol.70 (4), p.523-536

2010

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(16)
Life Sciences & Biomedicine
(16)
Male
(16)
Science & Technology
(16)
Female
(15)
Adult
(14)
Aged
(12)
Oncology
(10)
Pharmacology & Pharmacy
(9)
Pharmacokinetics
(8)
Pharmacology/toxicology
(7)
Pyrazoles - Adverse Effects
(6)
Pyrazoles - Pharmacokinetics
(6)
Quinolines - Adverse Effects
(6)
Quinolines - Pharmacokinetics
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Neoplasms - Drug Therapy
(5)
Patients
(5)
Pyrazoles - Administration & Dosage
(5)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials

Aktive Filter

Suchergebnisse filtern